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ABSTRACT
Mast cells are important modifiers of prostate tumor microenvironment. The 
fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) system 
plays a non-redundant autocrine/paracrine role in the growth, vascularization and 
progression of prostate tumors. Accordingly, the FGF antagonist long pentraxin-3 
(PTX3) and the PTX3-derived small molecule FGF-trap NSC12 have been shown 
to inhibit the growth and vascularization of different FGF-dependent tumor types, 
including prostate cancer. In this study, we show that recombinant FGF2 is able 
to cause mast cell recruitment in vivo in the Matrigel plug assay. Conversely, PTX3 
overexpression in transgenic mice or treatment with the FGF inhibitor NSC12 result in 
a significant inhibition of the growth and vascularization of TRAMP-C2 tumor grafts, 
a murine model of prostate cancer, that were paralleled by a decrease of mast cell 
infiltrate into the lesion. These data confirm and extend previous observations about 
the capacity of mast cells to respond chemotactically to FGF2 stimulation and provide 
evidence about a relationship among mast cell recruitment, angiogenesis, and tumor 
growth in human prostate adenocarcinoma.
INTRODUCTION
A tight cross-talk exists between inflammation and 
cancer, tumor-infiltrating inflammatory cells producing 
various cytokines that regulate the inflammatory 
response in the tumor-bearing host. Among inflammatory 
cells identified as important modifiers of tumor 
microenvironment, mast cells appear to play a crucial role 
[1]. Indeed, mast cells express a variety of growth factors/
angiogenic mediators and their accumulation correlates 
with increased neovascularization, tumor aggressiveness 
and poor prognosis in different solid and hematologic 
tumors [1].
Prostate tumors are a leading cause of death in 
the male population of Western countries [2]. Androgen 
receptor signalling plays a central role in prostate cancer, 
androgen deprivation therapy representing the first line 
of treatment for the advanced disease. However, tumors 
will eventually progress to an androgen-independent stage 
with poor prognosis. A correlation has been established 
between mast cell density and microvessel density in 
human prostate adenocarcinoma [3]. Tryptase-positive 
mast cells are present in both intratumoral and peritumoral 
areas of prostate adenocarcinoma with an overlapping 
mean density [4]. In addition, mast cell number in 
the intratumoral and peritumoral regions of prostate 
adenocarcinoma is significantly higher as compared to 
benign lesions [5]. Moreover, mast cells promote well-
differentiated adenocarcinoma growth in human patients 
and in the autochthonous transgenic adenocarcinoma of 
the mouse prostate (TRAMP) model [6].
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The members of the fibroblast growth factor 
(FGF) gene family [7] exert their activity by binding to 
tyrosine kinase FGF receptors (FGFRs) [8]. The FGF/
FGFR system plays a non-redundant autocrine/paracrine 
role in the growth, vascularization and progression of 
prostate tumors towards an hormone-refractory state as the 
consequence of the deregulation of FGFR signalling [9–
14]. Indeed, prostate tumors express various FGF family 
members, including FGF2 and FGF8b, with paracrine/
autocrine functions on cancer epithelial/stromal cells 
[11, 15, 16]. In particular, the FGF/FGFR system plays 
a prominent role during the growth of tumors obtained 
after grafting of androgen-dependent prostate TRAMP-C2 
cells in syngeneic mice [17–19]. Thus, TRAMP-C2 cells, 
originated from TRAMP mice [20], represent a model 
system suitable for the study of the effects of FGF/FGFR 
antagonists in the treatment of prostate cancer [21].
Long pentraxin-3 (PTX3) is a member of the 
pentraxin family produced locally in response to 
inflammatory signals [22]. PTX3 shares the C-terminal 
domain with short pentraxins and possesses a unique N-
terminal domain [22]. When assessed for the capacity to 
interact with a variety of growth factors/cytokines, PTX3 
was found to bind FGF2 via its N-terminal extension [23, 
24], thus inhibiting FGF2-dependent endothelial cell 
proliferation in vitro and angiogenesis in vivo [23–26]. 
In addition, PTX3 was found to inhibit the growth of 
various FGF-dependent tumor types (reviewed in [27]). 
On this basis, pharmacophore modeling of the interaction 
of a minimal PTX3-derived FGF-binding pentapeptide 
with FGF2 has been used for the identification of the 
first small molecule chemical (NSC12) which acts as an 
extracellular FGF trap with significant implications in 
cancer therapy [27].
In particular, previous observations had shown 
that PTX3 overexpression suppresses the angiogenic and 
tumorigenic potential of TRAMP-C2 cells by inhibiting 
the FGF-dependent autocrine/paracrine loop of stimulation 
driven by dihydrotestosterone [28]. Accordingly, 
injection of TRAMP-C2 cells in transgenic male mice 
overexpressing PTX3 under the control of the endothelial 
Tie2-promoter results in a significant inhibition of the 
growth and vascularization of the tumor graft [27]. Similar 
results were obtained when TRAMP-C2 cells were grafted 
in wild-type mice treated with the PTX3-derived small 
molecule FGF-trap [27].
Mast cells express FGFRs [29] and respond 
chemotactically to FGF2 stimulation [30]. Thus, the aim 
of this study was to investigate the capacity of FGF2 to 
induce an angiogenic response and mast cell recruitment 
in vivo in a murine Matrigel plug assay. Moreover, we 
have analyzed the impact of the inhibition of the FGF/
FGFR system by genetic and pharmacologic approaches 
on mast cell recruitment in prostate cancer. In a first 
set of experiments, FGF-dependent TRAMP-C2 cells 
were injected s.c. in syngeneic wild-type and in PTX3-
overexpressing transgenic TgN(Tie2-hPTX3) male 
mice. In a second set of experiments, TRAMP-C2 cells 
were grafted s.c. in wild type mice that were treated i.p. 
with the pan-FGF trap NSC12 inhibitor or the control 
compound NSC21. In both experimental conditions, 
immunohistochemical analysis was performed on 
harvested tumors to evaluate mast cell density in 
peripheral and central areas of the grafts and to correlate 
these values with the neovascular response in the same 
areas.
RESULTS
FGF2 recruits mast cells in the in vivo Matrigel 
plug assay
The capacity of FGF2 to induce an angiogenic 
response and mast cell recruitment was investigated in 
vivo by quantitative PCR analysis applied to a murine 
Matrigel plug assay [31]. As shown in Figure 1, FGF2-
treated plugs exert a remarkable neovascular and mast cell 
chemoattractant response, as showed by the significant 
upregulation of the expression of lineage specific 
endothelial CD31 and mast cell tryptase, chymase and 
CD117 transcripts in respect to control plugs. These 
data extend previous observations about the capacity of 
FGF2 to induce a chemotactic response on mast cells in 
vitro [30].
Impact of anti-FGF approaches on the growth of 
prostate TRAMP-C2 tumor grafts
Genetic and pharmacologic anti-FGF approaches 
were used to investigate the impact of the inhibition of the 
FGF/FGFR system on mast cell recruitment in prostate 
cancer. In a first set of experiments, FGF-dependent 
TRAMP-C2 cells were injected s.c. in syngeneic wild-
type and PTX3-overexpressing transgenic TgN(Tie2-
hPTX3) male mice. In a second set of experiments, 
TRAMP-C2 cells were grafted s.c. in wild type mice that 
were treated i.p. with the pan-FGF trap inhibitor NSC12 
(Supplementary Figure 1) or the control compound 
NSC21 [27]. In agreement with previous observations 
[27], both anti-FGF approaches resulted in a significant 
reduction of tumor weight at sacrifice (Figure 2). On this 
basis, harvested grafts were analyzed for vascularization 
and mast cell infiltration by immunohistochemistry.
PTX3 overexpression inhibits neovascularization 
and mast cell recruitment in prostate 
TRAMP-C2 tumor grafts
Immunohistochemical analysis was performed on 
sections of TRAMP-C2 tumor lesions originated in wild 
type (WT) and TgN(Tie2-hPTX3) mice in order to identify 
CD31-positive endothelial neovessels (Figure 3A-3D) 
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and the tryptase-positive mast cell infiltrate (Figure 4A-
4D) in the central and peripheral areas of tumor grafts. 
As shown in Figure 3, the density of CD31-positive cells 
was decreased in both central (13.56% ± SE 1.59%) 
and peripheral (17.50% ± SE 1.50%) areas of tumors 
harvested from TgN(Tie2-hPTX3) mice as compared 
to grafts obtained in WT animals (33.18% ± SE 1.33%, 
center; 38.79 ± SE 4.9%, periphery). Accordingly, 
tryptase-positive mast cell infiltrate was less abundant in 
both central and peripheral areas of TRAMP-C2 tumor 
grafts generated in transgenic mice (0.27% ± SE 0.04% 
and 0.52% ± SE 0.08%, respectively) as compared to that 
measured in WT animals (0.68% ± SE 0.12% and 0.89% 
± SE 0.05%, respectively) (Figure 4). Notably, mast cell 
infiltrate at the periphery of TRAMP-C2 tumor lesions 
grown in TgN(Tie2-hPTX3) mice appears to be more 
abundant than in the central areas of the lesion (*p< 0.05).
Figure 1: FGF2 induces an angiogenic response and mast cell recruitment in vivo. Matrigel plugs (n = 4–8) containing PBS or 
4.0 pmoles of FGF2 were implanted in the flank of female C57BL/6 mice. After 7 days, plugs were harvested and the levels of expression 
of lineage specific endothelial marker CD31 and mast cell tryptase, chymase and CD117 markers were assessed by qPCR analysis. Data are 
means ± SEM. *p < 0.05; **p < 0.01 versus PBS; Student’s t test.
Figure 2: Inhibition of prostate TRAMP-C2 tumor grafts by FGF inhibitors. (A) FGF-dependent TRAMP-C2 cells were 
injected s.c. in syngeneic wild-type and in PTX3-overexpressing transgenic TgN(Tie2-hPTX3) male mice that were sacrificed 37 days after 
grafting (n = 6). (B) TRAMP-C2 cells were grafted s.c. in wild type mice that were treated i.p., twice a week, with 7.5 mg/Kg of the pan-
FGF trap NSC12 or the control compound NSC21 starting from day 30 (n = 6-8) and sacrificed at day 49. Tumors were harvested, weighted 
and processed for IHC analysis. Data are means ± SEM. *P < 0.05; ***P < 0.001; Student’s t test.
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A small molecule FGF trap inhibits 
neovascularization and mast cell recruitment in 
prostate TRAMP-C2 tumor grafts
Similar to PTX3 overexpression, administration 
of the PTX3-derived small molecule FGF trap NSC12 
results in a significant inhibition of neovessel density and 
mast cell recruitment in TRAMP-C2 lesions generated 
by s.c. injection of tumor cells in syngeneic wild-type 
mice when compared to grafts grown in animals treated 
with vehicle (DMSO) or the control compound NSC21 
(Figures 5 and 6). Indeed, the density of CD31-positive 
endothelial cells was decreased in both central (4.26% ± 
SE 0.45%) and peripheral (5.56% ± SE 2.55%) areas of 
NSC12-treated samples as compared to NSC21-treated 
(12.54% ± SE 1.89%; 17.15± SE 1.02%) or DMSO-treated 
(10.89% ± SE 0.92%; 24.09 ± SE 2.86%) specimens 
(Figure 5). Similarly, tryptase-positive mast cell infiltrate 
was decreased in NSC12 samples in both central (0.44% 
± SE 0.06%) and peripheral (0.39% ± SE 0.01%) areas 
as compared to NSC21 (0.79% ± SE 0.05%; 0.75± SE 
Figure 3: Immunohistochemical (A-D) and morphometric analysis (E) of CD31 immunoreactivity in central (A-B) and peripheral (C-D) 
areas of TRAMP-C2 grafts harvested from wild type (WT) (A-C) and TgN(Tie2-hPTX3) (C-D) mice. The percentage of CD31-positive 
endothelial cells (E) decreases significantly in both central (B) and peripheral (D) areas of TgN(Tie2-hPTX3) samples as compared to WT 
samples (***p< 0.001). Scale bars: A-D, 60 μm. Data are reported as means ± SEM. Bonferroni post-test was used to compare all treatment 
groups after one-way ANOVA.
Figure 4: Immunohistochemical (A-D) and morphometric analysis (E) of tryptase immunoreactivity in central (A-B) and peripheral 
(C-D) areas of TRAMP-C2 grafts harvested from wild type (WT) (A-C) and TgN(Tie2-hPTX3) (C-D) mice. The percentage of tryptase-
positive mast cells (E) decreases significantly in both central (B) and peripheral (D) areas of TgN(Tie2-hPTX3) samples as compared to WT 
samples (*p< 0.05). Scale bars: A-D, 60 μm. Data are reported as means ± SEM. Bonferroni post-test was used to compare all treatment 
groups after one-way ANOVA.
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0.11%) and DMSO (0.8% ± SE 0.09%; 0.68 ± SE 0.01%) 
specimens (Figure 6).
DISCUSSION
The significant upregulation of the expression 
of the mast cell markers tryptase, chymase and CD117 
in FGF2-treated Matrigel plugs in respect to controls 
demonstrates that recombinant human FGF2 is able to 
induce a significant recruitment of mast cells in vivo when 
delivered s.c. in mice via a Matrigel plug. In addition, in 
keeping with the potent pro-angiogenic activity of this 
growth factor, mast cell recruitment was paralleled by a 
significant upregulation of the endothelial marker CD31 
in FGF2 plugs when compared to controls. Conversely, 
our data indicate that genetic or pharmacologic inhibition 
of the FGF/FGFR system in a murine model of prostate 
cancer results in a significant inhibition of tumor growth 
and neovascularization that are constantly associated to 
a reduction of mast cell density in both the peripheral 
and central areas of the tumor. These data confirm and 
extend previous observations about FGFR expression 
in mast cells [29] and the capacity of these cells to 
respond chemotactically to FGF2 stimulation in vitro 
[30]. In addition, they provide indirect evidence about a 
relationship among mast cell recruitment, angiogenesis, 
and tumor growth in human prostate adenocarcinoma. 
Although mast cell recruitment in the tumor tissues was 
reduced by FGF blockade, the decrease in vascularization 
appears to be more pronounced when compared to the 
reduction in the mast cell infiltrate. This may represent 
the consequence of the multi-targeting effects of anti-FGF 
approaches in the control of tumor angiogenesis that may 
Figure 5: Immunohistochemical (A-F) and morphometric analysis (G) of CD31 immunoreactivity in central (A-C) and peripheral (D-F) 
areas of TRAMP-C2 grafts harvested from wild-type mice treated i.p. with NSC21 (A-D), DMSO (B, E) or NSC12 (C-F). The percentage 
of CD31-positive endothelial cells (G) decreases significantly in both central (C) and peripheral (F) areas of NSC12-treated tumors as 
compared to DMSO- or NSC21-treated lesions (**p< 0.01) (A, B, D, E). Scale bars: A-D, 60 μm. Data are reported as means ± SEM. 
Bonferroni post-test was used to compare all treatment groups after one-way ANOVA.
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result in a direct inhibition of endothelial cells as well as of 
tumor and infiltrating stromal cells, including mast cells.
As observed for tumor-associated macrophages 
(TAMs), mast cells may exert both pro- and anti-tumor 
effects [32]. Indeed, mast cells induce immunosuppression 
by releasing tumor necrosis factor alpha (TNF-α) and 
interleukin10 (IL-10), involved in promoting the immune 
tolerance mediated by regulatory T cells [33, 34]. In 
addition, mast cells may promote inflammation, inhibition 
of tumor cell growth, and tumor cell apoptosis by releasing 
interleukin (IL)-1, IL-4, IL-6, IL-8, monocyte chemotactic 
protein-3 and-4 (MCP-3 and MCP-4), transforming 
growth factor beta (TGF-β), and chymase [1].
In prostate cancer, Fleischmann et al. [35] found 
a strong association among high mast cell counts and 
Gleason score, early tumor stage, and low risk for 
recurrence. At variance, Nonomura et al. [36] reported 
that a decreased number of mast cells correlates with a 
better prognosis in prostate cancer. Notably, Johansson et 
al. [37] demonstrated that prostate peritumoral mast cells 
stimulate angiogenesis and tumor growth by secreting 
FGF2 whereas intratumoral mast cells correlate negatively 
with the presence of metastases, tumor stage, Gleason 
score, angiogenesis, and tumor cell proliferation, being 
associated to a good prognosis. Mast cells synthesize and 
release potent angiogenic cytokines, including vascular 
endothelial growth factor (VEGF), FGF2, the serine 
proteases tryptase and chymase, IL-8, TGF-β, TNF-α 
and nerve growth factor (NGF) [40]. Mast cell-secreted 
molecules facilitate tumor vascularization not only by 
Figure 6: Immunohistochemical (A-F) and morphometric analysis (G) of tryptase immunoreactivity in central (A-C) and peripheral (D-F) 
areas of TRAMP-C2 grafts harvested from wild-type mice treated i.p. with NSC21 (A-D), DMSO (B, E) or NSC12 (C-F). The percentage 
of tryptase-positive mast cells (G) decreases significantly in both central (**p< 0.01) and peripheral (*p< 0.05) areas of NSC12-treated 
tumors (C, F) as compared to DMSO- or NSC21-treated lesions (A, B, D, E) (A-C, D-F). Scale bars: A-D, 60 μm. Data are reported as 
means ± SEM. Bonferroni post-test was used to compare all treatment groups after one-way ANOVA.
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a direct angiogenic effect but also by stimulating other 
inflammatory cells of the tumor microenvironment to 
release angiogenic mediators and cytokines as well as 
extracellular matrix-degrading proteases. Indeed, an 
increased number of mast cells have been demonstrated 
to be associated with angiogenesis in a variety vascular, 
haematological and solid tumors [40].
Mast cells have been indicated as a novel prognostic 
marker and a target for therapy associated with castration 
in prostate cancer [37]. In patients, mast cells are recruited 
to the tumoral compartment during the formation of 
castrate-resistant prostate tumors. In a rat orthotopic 
prostate tumor model, mast cells infiltrate tumors that 
relapse after an initial response to castration treatment. 
This occurs in association with increased angiogenesis and 
FGF2 upregulation [38, 39].
Mast cells might act as a new target for the 
adjuvant treatment of tumors through the selective 
inhibition of angiogenesis, tissue remodeling and 
tumor promoting molecules, allowing the secretion of 
cytotoxic cytokines and preventing mast cell mediated 
immune-suppression. Pre-clinical studies using anti-c-kit 
antibodies [40], anti-TNF-α antibodies [41], or the mast 
cells stabilizer disodium cromoglycate (cromolyn) [42] 
have demonstrated promising results in mouse models. 
Masatinib is a tyrosine kinase inhibitor that targets c-kit 
receptors and is clinically developed and approved for 
treatment of recurrent or unresectable grade III dog mast 
cell tumors and is the first approved anticancer drug in 
veterinary medicine [43]. Masatinib has been translated to 
human clinical trials for its evaluation in gastro intestinal 
stromal tumor (GIST), mastocytosis and pancreatic cancer 
[44, 45].
Here, in agreement with previous findings [27], we 
show that PTX3 overexpression or treatment with the 
PTX3-derived small molecule FGF trap NSC12 result 
in a significant inhibition of the growth of TRAMP-C2 
tumor grafts, a murine model of prostate cancer [20]. This 
was paralleled by a decrease of mast cell infiltrate into 
the lesion. This may represent the result of a multi-target 
effect of these anti-FGF approaches on different tumor 
compartments that may cause the inhibition of FGF-
mediated mast cell recruitment into the tumor and the 
inhibition of the mitogenic and angiogenic activity exerted 
by FGF molecules produced by the tumor parenchyma 
and stroma, including recruited mast cells. Even though 
further studies will be required to elucidate this complex 
interplay, our observations indicate that small FGF trap 
molecules may represent the basis for novel approaches 
in the therapy of prostate cancer [46]. In conclusion, this 
work provides further insights about the role of the FGF/
FGFR system and mast cells in the control of prostate 
tumor growth and angiogenesis, demonstrating for the 
first time in an in vivo prostate tumor model that mast cell 
recruitment at the tumor site and tumor neovascularization 
are two strictly FGF-dependent correlated events.
MATERIALS AND METHODS
Reagents and cell cultures
Compound NSC12 was synthesized by M. Mor 
(University of Parma, Italy) as described [47] and control 
compound NSC21 was provided by Drug Synthesis and 
Chemistry Branch, Developmental Therapeutics Program, 
Division of Cancer Treatment and Diagnosis, National 
Cancer Institute (USA). Human recombinant FGF2 
was from Tecnogen (Caserta, Italy). Murine prostate 
adenocarcinoma TRAMP-C2 cells were obtained from 
ATCC repository and maintained in DMEM supplemented 
with 10% heat inactivated FBS, 10 mM HEPES buffer, 
0.5 mM 2-mercaptoethanol, 2.0 mM glutamine, 5 mg/L 
bovine insulin (Sigma-Aldrich) and 10 nM DHT as 
described [28].
Matrigel plug angiogenesis assay
Six-week-old female C57BL/6 mice were injected 
subcutaneously (s.c.) with 400 μl of Matrigel (Trevigen, 
Gaithersburg, MD) containing PBS or 4.0 pmoles of 
FGF2. After 7 days, pellets were processed for total RNA 
extraction after adding to each plug a fixed amount of 
human cells as an internal standard [33]. Then, samples 
were analyzed for the expression of the indicated genes 
by real time quantitative PCR (qPCR) and data were 
normalized for human GAPDH expression levels as 
described [33]. To this purpose, total RNA was extracted 
from Matrigel plugs using TRIzol Reagent according to 
manufacturer’s instructions (Invitrogen). Contaminating 
DNA was digested using DNAse (Promega), 2.0 μg of 
total RNA were retro-transcribed with MMLV reverse 
transcriptase (Invitrogen) using random hexaprimers. 
Quantitative PCR was performed with a ViiATM 7 Real-
Time PCR Detection System (Applied Biosystems) 
using iQTM SYBR Green Supermix (Biorad) according 
to manufacturer’s instructions. In each experiment, an 
arbitrary value equal to 1.0 was assigned to the levels of 
expression of the gene(s) measured in one PBS Matrigel 
sample that was used as reference.
The following primers were used: murine CD31, 
5’-CGGTTATGATGATGTTTCTGGA (forward) and 
5’-AAGGGAGGACACTTCCACTTCT (reverse); murine 
Tryptase beta 2, 5’- CCTCTCCCACCTCCTTATCC 
(forward) and 5’-CCCTTCACTTTGCAGACCAG 
(reverse); murine Chymase 1, 5’ GGCAGAACAAACGT 
GAATGA (forward) and 5’-CTATCCCAGCACACAG 
CAGA (reverse); murine CD117, 5’-GTGAACCAACTTC 
GCCTGAC (forward) and 5’- GAATCCCTCTGCCAC 
ACACT (reverse); human GAPDH, 5’- GAAGGTCGGA 
GTCAACGGATT (forward) and 5’- TGACGGTGCCATG 
GAATTTG (reverse).
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In vivo tumor models
Wild-type C57BL/6 mice were purchased from 
Envigo (Correzzana, Italy). Transgenic TgN(Tie2-
hPTX3) mice overexpressing hPTX3 under the control 
of the endothelial specific Tie2 promoter were generated 
as described [27]. In a first set of experiments, nine-
week-old wild-type and TgN(Tie2-hPTX3) male mice 
were injected s.c. into the dorsolateral flank with 5x106 
TRAMP-C2 cells in 200 μl total volume of PBS and 
sacrificed at day 37. In a second set of experiments, 5x106 
TRAMP-C2 cells were injected s.c. into the dorsolateral 
flank of wild-type mice. After 30 days, vehicle (DMSO), 
NSC12 or NSC21 (both at 7.5 mg/kg) were injected i.p., 
twice a week, in 100 μl final volume. At the end of the 
experimental procedure (49 days after tumor cell grafting), 
tumors were harvested, weighted and paraffin embedded 
for immunohistochemical analysis of paraffin-embedded 
tumor sections.
CD31 and tryptase immunohistochemistry
Histological sections (4 μm thickness) were collected 
on poly-L-lysine-coated slides (Sigma Chemical, St Louis, 
MO, USA) and deparaffinized. Sections were rehydrated in 
a xylene-graded alcohol scale and then rinsed for 10 minutes 
in 0.1 M PBS. Sections were pre-treated with sodium citrate 
pH 6.1 (Dako Corporation, Milan, Italy) in Dako PT Link 
for antigen retrieval solution for 30 minutes at 98°C and 
then incubated with rabbit polyclonal anti-CD31 antibody 
(ab28364, Abcam, Cambridge, UK) or mouse monoclonal 
anti-tryptase antibody (NB-100-64820, Novus Biologicals, 
Littleton, CO, USA) diluted 1:60 and 1:1000, respectively. 
Then, sections were counterstained with Mayer hematoxylin 
and mounted in synthetic medium. Specific preimmune 
serum (Dako), replacing the primary antibodies, served as 
negative control. Sections from each experimental group (n 
= 10; 10 cases per group) were scanned using the whole-
slide morphometric analysis scanning platform Aperio 
Scanscope CS (Leica Biosystems, Nussloch, Germany). 
All the slides were scanned at the maximum available 
magnification (40×) and stored as digital high resolution 
images on the workstation associated with the instrument. 
Digital slides were inspected with Aperio ImageScope 
v.11 software (Leica Biosystems, Nussloch, Germany) at 
20× magnification and 10 fields with an equal area were 
selected for the analysis at 40× magnification. The protein 
expression was assessed with the Positive Pixel Count 
algorithm embedded in the Aperio ImageScope software 
and reported as positivity percentage, defined as the number 
of positively stained pixels on the total pixels in the image.
Statistical analysis
Data related to the experimental groups, WT and 
TgN(Tie2-hPTX3), NSC12, NSC21 and vehicle samples 
are reported as means ± SEM. Bonferroni post-test was 
used to compare all treatment groups after one-way 
ANOVA. The Graph Pad Prism 5.0 statistical package 
(GraphPad Software, San Diego, CA, USA) was used for 
analyses and the limit for statistical significance was set 
at P˂0.05.
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